Novel Rx
![](https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg)
9 months 3 weeks ago
Treatment of RA-ILD patients with ABA at any time of the course in the ILD seems to prevent interstitial lung progression. The evolution of FVC and DLCO for 48 months remained stable with ABA therapy. Serrano-Combarro A, Abst#2173 #ACR23 @RheumNow https://t.co/QE61wzKWXi https://t.co/xd3wvMXUlA
![](https://pbs.twimg.com/media/F_AE2rIaAAA3J-8.jpg)
![](https://pbs.twimg.com/profile_images/1324821320429981703/dAiq_hpT_normal.jpg)
9 months 3 weeks ago
Continued interest on CAR-T cells in systemic sclerosis!
6 mo f/up data on 3 pts who received CAR-T cell treatment - stable dz overall
Skin findings improved in all 3 pts
Previous finger ulcerations resolved
Lung function stable in 2 pts, improved in 1
@RheumNow #ACR23 Abs#2598
![](https://pbs.twimg.com/profile_images/847812732007133184/hIbnEHt3_normal.jpg)
9 months 3 weeks ago
#ACR23 Abs 2598 show data on 1st 3 CD19 CAR-T treated SSc pts. Tx well tolerated and dz stabilized off tx x 6 months. Promising, but more data needed for further evaluation. https://t.co/RAKhT6Eygn @rheumnow
![](https://pbs.twimg.com/profile_images/1324821320429981703/dAiq_hpT_normal.jpg)
9 months 3 weeks ago
Interesting late breaker!
Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA
Phase 3 study - at wk 24, reached ACR20, ACR50, DAS28-ESR, no radiographic progression
No difference in safety profile compared to placebo
@RheumNow #ACR23 #ACRBest https://t.co/bxWPagGixt
![](https://pbs.twimg.com/media/F-8Ep_DXcAADZTB.png)
![](https://pbs.twimg.com/profile_images/1625445768768135171/M24lCgC__normal.jpg)
9 months 3 weeks ago
#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest https://t.co/Rj1k1z0Tsz
![](https://pbs.twimg.com/media/F-_h6VcWUAARqtX.jpg)
![](https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3_normal.jpg)
9 months 3 weeks ago
Window of opportunity for abatacept in RA-ILD. Early treated patients (<6 months vs >2 years) appear to do better in terms of FVC. Abstr#2173 #ACR23 @RheumNow https://t.co/14IsA1KbAk https://t.co/ZbZEwzaOu0
![](https://pbs.twimg.com/media/F-5G4qpXcAEUx8l.png)
![](https://pbs.twimg.com/profile_images/908324013566513153/YdK61O5C_normal.jpg)
9 months 3 weeks ago
L20 @ #ACR23
New therapy on the horizon for RA pts that failed MTX?
⭐️Telitacicept = recombinant fusion protein targeting & neutralizing BLyS & APRIL
➡️ placebo-controlled, phase III trial, 24w
👉at wk 24, PBO pts switched to drug arm for 24 more wks
➡️ 479 pts w/… https://t.co/94MyC8sdaG https://t.co/x3MUmFJPK6
![](https://pbs.twimg.com/media/F-_ismbXYAEO5LN.jpg)
![](https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3_normal.jpg)
9 months 3 weeks ago
Will CAR T Cells also treat RA?
Dr. Jonathan Kay reports on abstract 0424 from #ACR23.
https://t.co/XvNMXAFkWe https://t.co/HVvBLhqe8H
![](https://pbs.twimg.com/media/F-_K3xYX0AAdYJb.jpg)